Iovance Biotherapeutics (IOVA) Analyst Sentiment Remains Strong Amid U.S. Rollout of Melanoma Drug Amtagvi

Iovance Biotherapeutics (IOVA) has a strong analyst sentiment with 73% of covering analysts retaining bullish ratings, a consensus price target of $9.50, and a potential upside of 135.15%. The company is advancing its pipeline products in lung cancer and sarcoma, expanding the U.S. rollout of its melanoma drug Amtagvi, and reporting a 50% gross margin in Q4. Regulatory decisions for Amtagvi are expected in H1 2026.